Multiple myeloma is an incurable hematologic cancer of plasma cells characterized by increased monoclonal (M) protein levels due to proliferation of malignant clonal plasma cells.1-4 Plasma cells transform into malignant myeloma cells through the acquisition of genetic events, activation of key signaling pathways, and aberrant stromal and cellular signaling.5-12 The pathophysiology of multiple myeloma is characterized by promotion of immune dysregulation, malignant plasma cell survival, and aberrant stromal-cell support.5,13-17 Multiple myeloma is associated with regrowth of residual tumor and immune suppression.18,19 Malignant plasma cells are able to evade detection by the immune system through altering their phenotype and simultaneously inducing the production of immune-suppressing cytokines and other molecules.19
In multiple myeloma, significant treatment advances have been made. Some areas of research focus on the high burden of both the disease and its treatments, identifying treatment strategies for specific populations (including transplant-ineligible patients and elderly, unfit, and high-risk patients), the role of salvage therapies, treatment-resistant disease, and clonal evolution.20-22 The current landscape continues to expand, and investigational therapies include cereblon E3 ligase modulators, antibodies targeting plasma cells, chimeric antigen receptor T cell therapy, bi-specific T-cell engager antibodies, and antibody-drug conjugates.21-23
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.
Clinical trial information is sourced from ClinicalTrials.gov. Information is updated manually as clinical trials are published. The efficacy and safety of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.